Amicus Therapeutics, Inc. (FOLD) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Philadelphia, PA, United States. The current CEO is Bradley L. Campbell.
FOLD has IPO date of 2007-05-31, 499 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $4.54B.
Amicus Therapeutics, Inc. is a biotechnology company headquartered in Philadelphia that specializes in discovering, developing, and commercializing medicines for rare genetic diseases. The company's lead commercial product is Galafold, an oral precision medicine approved for treating adults with Fabry disease who carry amenable galactosidase alpha gene variants. Its pipeline includes AT-GAA for Pompe disease, AT-GTX-502, a gene therapy in Phase 1/2 development for CLN3 disease, and a gene therapy program targeting CDKL5 deficiency. Amicus maintains strategic collaborations with major research institutions including Nationwide Children's Hospital, University of Pennsylvania, and GlaxoSmithKline to advance its development programs. Founded in 2002, the company is focused on addressing significant unmet medical needs in the rare disease community.
